Achieve Life Sciences, Inc. (ACHV) financial statements (2021 and earlier)

Company profile

Business Address 520 PIKE STREET
SEATTLE, WA 98101
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3622121217710
Cash and cash equivalents3622121217710
Other undisclosed cash, cash equivalents, and short-term investments    0  
Receivables    0  
Prepaid expense    1  
Other undisclosed current assets1211(0)00
Total current assets:3724131317811
Noncurrent Assets
Operating lease, right-of-use asset000000 
Property, plant and equipment0000000
Intangible assets, net (including goodwill)3333333
Goodwill1111111
Intangible assets, net (excluding goodwill)2222222
Restricted cash and investments0000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets      0
Total noncurrent assets:3444444
TOTAL ASSETS:40281617211115
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2221222
Accounts payable0010111
Accrued liabilities1000000
Employee-related liabilities1110111
Debt   000 
Other undisclosed current liabilities1001011
Total current liabilities:3222333
Noncurrent Liabilities
Long-term debt and lease obligation000000 
Operating lease, liability000000 
Other undisclosed noncurrent liabilities(0)(0)(0)   0
Total noncurrent liabilities: 000000
Total liabilities:3222333
Stockholders' equity
Stockholders' equity attributable to parent3726151518812
Common stock0000000
Additional paid in capital98816664645150
Accumulated other comprehensive income0000000
Accumulated deficit(60)(56)(52)(49)(46)(43)(39)
Total stockholders' equity:3726151518812
TOTAL LIABILITIES AND EQUITY:40281617211115

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(5)(4)(3)(3)(3)(4)(4)
Operating loss:(5)(4)(3)(3)(3)(4)(4)
Nonoperating income (expense)(0)(0)(0)0000
Investment income, nonoperating0000000
Other nonoperating income (expense)(0)(0)(0)(0)(0)0(0)
Loss before gain (loss) on sale of properties:(5)(4)(3)(3)(3)(4)(4)
Other undisclosed net income (loss)0  0(0)  
Net loss available to common stockholders, diluted:(5)(4)(3)(3)(3)(4)(4)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(5)(4)(3)(3)(3)(4)(4)
Comprehensive loss, net of tax, attributable to parent:(5)(4)(3)(3)(3)(4)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: